Meeting of the Vaccine Safety Working Group, 15524 [E8-5892]

Download as PDF 15524 Federal Register / Vol. 73, No. 57 / Monday, March 24, 2008 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the Vaccine Safety Working Group Department of Health and Human Services, Office of the Secretary. ACTION: Notice. mstockstill on PROD1PC66 with NOTICES AGENCY: SUMMARY: The Department of Health and Human Services (DHHS) is hereby giving notice that the National Vaccine Program Office (NVPO) will convene a meeting of NVAC’s Vaccine Safety Working Group. The meeting is open to the public. DATES: The meeting will be held on April 11, 2008, from 9 a.m. to 5 p.m. ADDRESSES: Department of Health and Human Services; Hubert H. Humphrey Building, Room 705A; 200 Independence Avenue, SW., Washington, DC 20201. FOR FURTHER INFORMATION CONTACT: Daniel Salmon, Vaccine Safety Specialist, National Vaccine Program Office, Department of Health and Human Services, Room 443-H Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201; (202) 260–1587 or daniel.salmon@hhs.gov. SUPPLEMENTARY INFORMATION: NVPO has responsibility for coordinating and ensuring collaboration among the many Federal agencies involved in vaccine and immunization activities. The NVPO provides leadership and coordination among Federal agencies, as they work together to carry out the goals of the National Vaccine Plan. The National Vaccine Plan provides a framework, including goals, objectives, and strategies, for pursuing the prevention of infectious diseases through immunizations. NVPO periodically convenes groups to address specific issues and topics that impact vaccine and immunization. The Vaccine Safety Working Group has been established to (1) undertake and coordinate a scientific review of the draft Immunization Safety Office (Centers for Disease Control and Prevention) research agenda, and (2) review the current vaccine safety system. Following the advice of the Institute of Medicine in its report ‘‘Vaccine Safety Research, Data Access and Public Trust’’ (February 17, 2005), this meeting of the Working Group is open to the public, noting that pubic attendance is limited to space available. Individuals must provide a photo ID for entry into the Humphrey Building. Individuals VerDate Aug<31>2005 16:33 Mar 21, 2008 Jkt 214001 who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the designated contact person. Members of the public will have the opportunity to provide comments at the meeting. Public comment will be limited to five minutes per speaker. Any members of the public who wish to have printed material distributed to meeting participants should submit materials to the NVPO staff person designated as the contact for additional information. All materials should be submitted to the designated point of contact no later than close of business April 9, 2008. Preregistration is required for both public attendance and comment. Any individual who wishes to attend the meeting and/or participate in the public comment session should contact the designated staff member, Daniel Salmon, by e-mail daniel.salmon@hhs.gov or call 202– 690–5566. Dated: March 18, 2008. Bruce Gellin, Director, National Vaccine Program Office. [FR Doc. E8–5892 Filed 3–21–08; 8:45 am] BILLING CODE 4150–44–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [60Day–08–08AU] Proposed Data Collections Submitted for Public Comment and Recommendations In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 404–639–5960 and send comments to Maryam Daneshvar, CDC Acting Reports Clearance Officer, 1600 Clifton Road, MS–D74, Atlanta, GA 30333 or send an e-mail to omb@cdc.gov. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice. Proposed Project Assessing Problem Areas in Referrals for Chronic Hematologic Malignancies and Developing Interventions to Address Them—New—Division of Cancer Prevention and Control (DCPC), National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC). Background and Brief Description: One of the six aims of the Insitute of Medicine’s Crossing the Quality Chasm report is to improve the timeliness of care for patients. Data from Europe and Canada, as well as single-site studies in the United States, allude to a problem of timely referral and diagnosis for patients with cancer. Despite the advent of new diagnostics and therapeutics for patients with chronic hematological malignancies, the size and scope of a potential problem regarding their referral from primary care providers to specialists is not well-defined in the current literature. CDC proposes to conduct a one-time study to collect qualitative and quantitative information on optimal and sub-optimal referral patterns for patients with confirmed or suspected chronic hematologic malignancies. Information will be collected to identify specific factors related to delays in diagnosis and/or referral to appropriate medical specialists. Information will be collected through in-depth interviews with hematologic cancer patients, in-depth interviews and focus groups with primary care providers, interviews with specialists in hematology and oncology in Texas, and a one-time postal survey to a sample of primary care providers (physicians and advance practice nurses) in Massachusetts. The ultimate goal is to develop tools that will improve the awareness, diagnosis, and referral of persons with chronic hematological cancers by primary care providers. There are no costs to respondents other than their time. E:\FR\FM\24MRN1.SGM 24MRN1

Agencies

[Federal Register Volume 73, Number 57 (Monday, March 24, 2008)]
[Notices]
[Page 15524]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-5892]



[[Page 15524]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Vaccine Safety Working Group

AGENCY: Department of Health and Human Services, Office of the 
Secretary.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (DHHS) is hereby 
giving notice that the National Vaccine Program Office (NVPO) will 
convene a meeting of NVAC's Vaccine Safety Working Group. The meeting 
is open to the public.

DATES: The meeting will be held on April 11, 2008, from 9 a.m. to 5 
p.m.

ADDRESSES: Department of Health and Human Services; Hubert H. Humphrey 
Building, Room 705A; 200 Independence Avenue, SW., Washington, DC 
20201.

FOR FURTHER INFORMATION CONTACT: Daniel Salmon, Vaccine Safety 
Specialist, National Vaccine Program Office, Department of Health and 
Human Services, Room 443-H Hubert H. Humphrey Building, 200 
Independence Avenue, SW., Washington, DC 20201; (202) 260-1587 or 
daniel.salmon@hhs.gov.

SUPPLEMENTARY INFORMATION: NVPO has responsibility for coordinating and 
ensuring collaboration among the many Federal agencies involved in 
vaccine and immunization activities. The NVPO provides leadership and 
coordination among Federal agencies, as they work together to carry out 
the goals of the National Vaccine Plan. The National Vaccine Plan 
provides a framework, including goals, objectives, and strategies, for 
pursuing the prevention of infectious diseases through immunizations. 
NVPO periodically convenes groups to address specific issues and topics 
that impact vaccine and immunization.
    The Vaccine Safety Working Group has been established to (1) 
undertake and coordinate a scientific review of the draft Immunization 
Safety Office (Centers for Disease Control and Prevention) research 
agenda, and (2) review the current vaccine safety system.
    Following the advice of the Institute of Medicine in its report 
``Vaccine Safety Research, Data Access and Public Trust'' (February 17, 
2005), this meeting of the Working Group is open to the public, noting 
that pubic attendance is limited to space available. Individuals must 
provide a photo ID for entry into the Humphrey Building. Individuals 
who plan to attend and need special assistance, such as sign language 
interpretation or other reasonable accommodations, should notify the 
designated contact person. Members of the public will have the 
opportunity to provide comments at the meeting. Public comment will be 
limited to five minutes per speaker. Any members of the public who wish 
to have printed material distributed to meeting participants should 
submit materials to the NVPO staff person designated as the contact for 
additional information. All materials should be submitted to the 
designated point of contact no later than close of business April 9, 
2008. Pre-registration is required for both public attendance and 
comment. Any individual who wishes to attend the meeting and/or 
participate in the public comment session should contact the designated 
staff member, Daniel Salmon, by e-mail daniel.salmon@hhs.gov or call 
202-690-5566.

    Dated: March 18, 2008.
Bruce Gellin,
Director, National Vaccine Program Office.
[FR Doc. E8-5892 Filed 3-21-08; 8:45 am]
BILLING CODE 4150-44-P